Risk Mitigation Through FDA Q-Submission Consulting

Short Description

The FDA Q-Submission Program is an important regulatory pathway that helps Medical Device sponsors reduce potential risks before submitting a formal application. By obtaining early FDA feedback, sponsors can clarify regulatory expectations, improve study planning, and address development challenges at an early stage. This allows better planning, supports informed decision-making, and reduces uncertainty during product development. By taking action at an early stage, unnecessary delays can be avoided, and it helps to support a smoother FDA submission and approval.

Understanding FDA Risk Mitigation Through Early FDA Feedback

FDA Risk Mitigation begins before a Medical Device is submitted to the Food and Drug Administration (FDA). The FDA Q-Submission Program allows sponsors to request FDA feedback during product development. This feedback helps sponsors address regulatory questions pre-market submission. It is especially useful when existing guidance does not fully address a specific regulatory issue.¹ 

Interacting with the FDA in the early stages help to reduce regulatory uncertainty during product development. FDA feedback obtained before planned testing helps to improve study planning and submission preparation. This feedback may improve the quality of future submissions, support a more efficient review process, and shorten overall review timelines. Although participation is voluntary, it helps the sponsors to strengthen their regulatory planning before formal submission.² 

Preparing a Strong Q-Submission for Better Regulatory Risk Management

Planning is an important part of FDA Risk Mitigation.¹ A well-prepared Q-Submission helps the FDA understand the purpose of the request and the stage of product development. When the required information is organised before submission, the FDA can provide more accurate and useful feedback.² 

A strong Q-submission for better regulatory risk management should include:

• The purpose of the Q-Submission and the type of future submission being planned.² 
• A summary of previous FDA discussions related to the device. 
• An overview of completed or planned non-clinical and clinical testing.¹ 
• Relevant guidance documents, regulations, or standards that support the proposed approach.² 

Preparing these details before requesting FDA feedback can improve communication between the sponsor and the FDA. It also allows the FDA to develop feedback based on the information provided for the specific device and proposed submission². 

Developing Effective Questions to Reduce Regulatory Risks

To obtain feedback from FDA on specific regulatory concerns before they become challenges during device development, effective questions need to be included in the Q-Submission. A Pre-Submission should include clear and focused questions related to review issues associated with a planned submission.¹ 

Developing effective questions in a FDA Q-Submission can help reduce regulatory risks by:

• Focusing on specific concerns: FDA provides feedback on areas that are important for decision-making when targeted questions are asked mainly on specific regulatory aspects rather than asking generally.
• Including proposed approaches: Questions related to study protocols or testing methods should include the proposed approach and rationale. This allows FDA to provide more useful feedback. 
• Limiting the number of questions: FDA recommends focusing on a limited number of important topics and 7-10 questions to support productive discussions and detailed feedback.² 

Managing Clinical Study Risks Through Study Risk Determination

Study Risk Determination is a Q-Submission pathway that allows sponsors to obtain FDA’s determination on whether a planned Medical Device clinical investigation is Significant Risk (SR), Non-Significant Risk (NSR), or exempt from Investigational Device Exemption (IDE) requirements.^,3

A Study Risk Determination request should include the proposed study protocol and relevant information about the device to allow FDA to evaluate the planned investigation.⁴ 

The process helps sponsors by:

• Clarifying regulatory responsibilities: FDA reviews the proposed clinical study and issues a letter indicating whether the study is exempt, Significant Risk, or Non-Significant Risk.¹ 
• Supporting clinical study planning: FDA can assist sponsors, investigators, and Institutional Review Boards in evaluating the risk category of the planned study.² 
• Providing a final risk determination: FDA’s determination is final regarding whether a device study is Significant Risk or Non-Significant Risk.^2,3 

Managing Future Submission Risks Through FDA Feedback

FDA feedback obtained through a Q-Submission helps in future regulatory planning; however, sponsors should ensure that the feedback remains applicable as device development progresses. FDA feedback is based on the information provided during the Pre-Submission and the knowledge available at that time.² 

Sponsors can manage future submission risks by:

• Using previous feedback: Any relevant previous communications with the FDA should be included in future submissions and explain how it was addressed. If a different approach is selected, the reasons for choosing that approach should also be provided. 
• Confirming older FDA advice: If more than one year has passed since receiving FDA feedback and the planned study has not started, sponsors should contact the review division to confirm whether the previous advice is still applicable. 
• Seeking additional FDA discussion when needed: If further review or discussion is required, FDA may recommend submitting a new Pre-Submission to address additional topics.

This helps sponsors maintain consistency between FDA discussions and future regulatory submissions.

How FDA Q-Submission Consulting Supports Risk Mitigation

FDA Q-Submission consulting can help sponsors identify and manage regulatory challenges during Medical Device development. By keeping an effective interaction with FDA, it helps sponsors make informed decisions and manage potential issues before formal submission.¹

The table below shows how FDA Q-Submission consulting helps sponsors manage regulatory challenges during device development.

Table 1

Conclusion

FDA Risk mitigation is essential for reducing regulatory challenges during Medical Device development. The FDA Q-Submission Program helps sponsors identify potential risks early and obtain FDA feedback before preparing a formal submission. This allows better planning, improves regulatory decision-making, and reduces uncertainty during the development process. FDA Q-Submission consulting also supports the sponsors by helping them address any regulatory concerns, prepare stronger submissions, and to have a smoother and more efficient FDA review. 

References 

1. Piermatteo K. The Pre-Submission Program and Meetings with FDA Staff. U.S. Food and Drug Administration; 2016. Accessed July 8, 2026. https://www.fda.gov/media/93744/download

2. U.S. Food and Drug Administration. Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program; Guidance for Industry and Food and Drug Administration Staff. U.S. Food and Drug Administration; 2025. https://www.fda.gov/media/114034/download

3. Q-Submission (Pre-IDE) Meetings | Office of Ethics and Compliance. Accessed July 8, 2026. https://compliance.ucsf.edu/q-submission-pre-ide-meetings

4. University of California, San Francisco (UCSF). Study Risk Determination Template. Published online 2025. https://compliance.ucsf.edu/sites/compliance.ucsf.edu/files/2025-02/Study_Risk_Determination_Template.docx